Patient Prostate Cancer Guidelines Available

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 7
Volume 8
Issue 7

NEW YORK--The National Comprehensive Cancer Network (NCCN) and the American Cancer Society (ACS) have collaborated to translate the NCCN prostate cancer guidelines into a patient-friendly resource for appropriate treatment, the two organizations announced at a press briefing.

NEW YORK--The National Comprehensive Cancer Network (NCCN) and the American Cancer Society (ACS) have collaborated to translate the NCCN prostate cancer guidelines into a patient-friendly resource for appropriate treatment, the two organizations announced at a press briefing.

Incorporating the clinical experience of the 17 NCCN member institutions, these guidelines offer prostate cancer patients and their families the reliable, specific, and easy-to-understand information they need to make treatment decisions.

In March, the NCCN and ACS released breast cancer guidelines for patients, resulting in 1.5 million visits to the NCCN website.The prostate cancer guidelines are available on the NCCN website (www.nccn.org),and the ACS website (www.cancer.org).

The prostate cancer treatment guidelines for patients will also be published in the August/September 1999 issue of InTouch, PRR, Inc.’s cancer magazine for consumers.

Recent Videos
Immunotherapy-based combinations may elicit a synergistic effect that surpasses monotherapy outcomes among patients with muscle-invasive bladder cancer.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Biochemical markers and advanced imaging modalities play a critical role in monitoring patients undergoing RLT therapy for metastatic prostate cancer.
Data support the use of radioligand therapy in combination with androgen receptor pathway inhibitors to optimize prostate cancer outcomes.
Experts weigh in on tumor-informed testing, false positives, relevant trial data, and other key concepts related to circulating tumor DNA.
Ongoing studies in kidney cancer aim to explore determinants of immune-related adverse effects and strategies for mitigating them.
Machine learning-based approaches may play a role in further understanding of how somatic alterations influence responses or resistance to therapy.
Data from a first-in-disease trial assessing a personalized cancer vaccine in RCC require validation at a larger level, according to David Braun, MD, PhD.
Related Content